The application of CRISPR–Cas13 for targeted RNA degradation is hindered by the existence of collateral effects induced by Cas13. We screened hundreds of engineered Cas13 variants using a convenient and sensitive reporter system and obtained several variants with markedly reduced collateral activity and efficient on-target activity, suitable for in vivo applications.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Smargon, A. A., Shi, Y. J. & Yeo, G. W. RNA-targeting CRISPR systems from metagenomic discovery to transcriptomic engineering. Nat. Cell Biol. 22, 143–150 (2020). A Review article that presents progress in the RNA-targeting CRISPR–Cas field, including the applications of Cas13 for RNA biology.
Zhang, C. et al. Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d. Cell 175, 212–223.e217 (2018). This paper reports the molecular and structural basis for Cas13d function, including both guide and target RNA recognition.
Slaymaker, I. M. et al. High-resolution structure of Cas13b and biochemical characterization of RNA targeting and cleavage. Cell Rep. 26, 3741–3751.e3745 (2019). This paper reports a high-resolution structure of Cas13b and demonstrates that Cas13b can be rationally engineered to change RNA cleavage specificity.
Wang, Q. et al. The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv. Sci. (Weinh.) 6, 1901299 (2019). This paper reports collateral effects of the CRISPR–Cas13a system in eukaryotes for the first time and demonstrates the powerful tumor-eliminating potential of this system.
Ai, Y., Liang, D. & Wilusz, J. E. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 50, e65 (2022). This paper reports that Cas13d and Cas13b have differing extents of off-target effects and highlights the need for caution when using Cas13 effectors in eukaryotic cells.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Tong, H. et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01419-7 (2022).
Rights and permissions
About this article
Cite this article
Engineered Cas13 variants with minimal collateral RNA targeting. Nat Biotechnol 41, 29–30 (2023). https://doi.org/10.1038/s41587-022-01423-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01423-x